HealthdirectFree Australian health advice you can count on.

( ARTG ) INDICATIONS AS AT 11 APRIL 2002 : ATGAM is indicated for renal transplant patients in whom reduction of peripheral T-lympocyte function as measured by rosette-forming cell assay could be desirable.‍​‍‍‍​‍‍‍‍‍‍‍‍​‍ During controlled clinical trials, this immunosuppression has been demonstrated in renal allograft recipients treated with ATGAM. When it was administered prophylactically with conventional immunosuppressive therapy, ATGAM delayed the onset of the first rejection episode, and when it was administered at the time of the first rejection, ATGAM resolved the acute rejection episode more frequently than did conventional therapy alone.